标题
Signalling in pancreatic cancer: from pathways to therapy
作者
关键词
-
出版物
JOURNAL OF DRUG TARGETING
Volume -, Issue -, Pages 1-14
出版商
Informa UK Limited
发表日期
2023-10-23
DOI
10.1080/1061186x.2023.2274806
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma
- (2023) Jian Li et al. Cancer Cell International
- Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models
- (2023) Liangping Su et al. Science Translational Medicine
- A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer
- (2023) Yan Du et al. Biomed Research International
- Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer
- (2023) Shumin Li et al. CANCER LETTERS
- Ferroptosis regulates key signaling pathways in gastrointestinal tumors: Underlying mechanisms and therapeutic strategies
- (2023) Ravichandiran Rabitha et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Starvation mediates pancreatic cancer cell sensitivity to ferroptosis via ERK1/2, JNK and changes in the cell mesenchymal state
- (2022) Egle Zalyte et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
- (2022) Changsong Qi et al. NATURE MEDICINE
- Copper induces cell death by targeting lipoylated TCA cycle proteins
- (2022) Peter Tsvetkov et al. SCIENCE
- Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
- (2022) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer
- (2022) Liqing Lu et al. Cell Death Discovery
- Cuproptosis-related gene index: A predictor for pancreatic cancer prognosis, immunotherapy efficacy, and chemosensitivity
- (2022) Xufeng Huang et al. Frontiers in Immunology
- Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer
- (2022) Wenkai Jiang et al. Canadian Journal of Gastroenterology and Hepatology
- Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
- (2022) Katrin J. Frank et al. Cell Reports Medicine
- Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma
- (2021) Cara Kenney et al. INVESTIGATIONAL NEW DRUGS
- Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
- (2021) Davide Melisi et al. Journal for ImmunoTherapy of Cancer
- Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling
- (2021) Jing Cui et al. MOLECULAR MEDICINE
- Hedgehog signaling mechanism and role in cancer
- (2021) Jin Jiang SEMINARS IN CANCER BIOLOGY
- Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma
- (2021) Yuqiong Wang et al. Frontiers in Oncology
- Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape
- (2021) Ji Eun Lee et al. CANCER LETTERS
- Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
- (2021) Giuseppe Curigliano et al. EUROPEAN JOURNAL OF CANCER
- Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor
- (2021) Hsin-Han Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma
- (2021) Shirin Hafezi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pancreatic Cancer
- (2021) Wungki Park et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Emerging strategies to target RAS signaling in human cancer therapy
- (2021) Kun Chen et al. Journal of Hematology & Oncology
- Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence
- (2021) Xufeng Tao et al. PHARMACOLOGICAL RESEARCH
- Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer
- (2021) Jiewei Lin et al. Cell Death & Disease
- Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease
- (2021) Ashley N. Sigafoos et al. Cancers
- Engineering of an EpCAM-targeting cyclic peptide to improve the EpCAM-mediated cellular internalization and tumor accumulation of a peptide-fused antibody
- (2021) Seong-Wook Park et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer
- (2021) Ji Eun Lee et al. Biomolecules & Therapeutics
- LncRNA MIR99AHG mediated by FOXA1 modulates NOTCH2/Notch signaling pathway to accelerate pancreatic cancer through sponging miR-3129-5p and recruiting ELAVL1
- (2021) Jin Xu et al. Cancer Cell International
- Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
- (2021) Jianhui Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
- (2021) Daolin Tang et al. Molecular Cancer
- Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives
- (2021) Xiaoqi Mao et al. Molecular Cancer
- RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging
- (2021) Margie N. Sutton et al. MOLECULAR IMAGING AND BIOLOGY
- Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
- (2021) Esther N. Pijnappel et al. Cancers
- Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
- (2020) Jia-qiao Fan et al. Molecular Cancer
- Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer
- (2020) Dirk Bausch et al. ANGIOGENESIS
- New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
- (2020) Ritu Raj Singh et al. DRUGS
- Gasdermin E suppresses tumour growth by activating anti-tumour immunity
- (2020) Zhibin Zhang et al. NATURE
- A bioorthogonal system reveals antitumour immune function of pyroptosis
- (2020) Qinyang Wang et al. NATURE
- Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as 1 st ‐line treatment in patients with metastatic pancreatic adenocarcinoma ( GATE 1)
- (2020) Eric Assenat et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination
- (2020) Ryan M. Carr et al. PANCREATOLOGY
- Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
- (2020) Irem Ozkan-Dagliyan et al. Cell Reports
- Deubiquitinase USP18 promotes the progression of pancreatic cancer via enhancing the Notch1-c-Myc axis
- (2020) Long Feng et al. Aging-US
- Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways
- (2020) Yangyang Guo et al. CELL BIOLOGY AND TOXICOLOGY
- CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results
- (2020) M. Sinn et al. EUROPEAN JOURNAL OF CANCER
- Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer
- (2020) Namrata Khurana et al. Cancers
- Hedgehog Signaling and Truncated GLI1 in Cancer
- (2020) Daniel Doheny et al. Cells
- Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- (2020) Shuo Chen et al. Frontiers in Oncology
- Glasdegib: First Global Approval
- (2019) Sheridan M. Hoy DRUGS
- Triptolide suppresses pancreatic cancer cell proliferation by inhibiting hedgehog signaling pathway activity
- (2019) Juanjuan Feng et al. Science China-Life Sciences
- AKT as a Therapeutic Target for Cancer
- (2019) Mengqiu Song et al. CANCER RESEARCH
- microRNA-365a-3p inhibits c-Rel-mediated NF-κB signaling and the progression of pancreatic cancer
- (2019) Libo Yin et al. CANCER LETTERS
- FDA Approval Summary: Glasdegib for newly-diagnosed acute myeloid leukemia
- (2019) Kelly J. Norsworthy et al. CLINICAL CANCER RESEARCH
- Sequential Targeting TGF‐β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer
- (2019) Yuanyuan Pei et al. Small
- Triptolide and Its Derivatives as Cancer Therapies
- (2019) Pawan Noel et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Copper (II) Ions Activate Ligand-Independent Receptor Tyrosine Kinase (RTK) Signaling Pathway
- (2019) Fang He et al. Biomed Research International
- Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
- (2019) Heng Sheng Sow et al. Cells
- RAS mutations in human cancers: Roles in precision medicine
- (2019) Avaniyapuram Kannan Murugan et al. SEMINARS IN CANCER BIOLOGY
- Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts
- (2019) Ela Elyada et al. Cancer Discovery
- A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
- (2019) Zishuo Ian Hu et al. Cancer Medicine
- Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer
- (2019) Niranjan Awasthi et al. CANCER LETTERS
- Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis
- (2019) Tobias Forster et al. ONCOLOGY
- Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
- (2019) G. Aaron Hobbs et al. Cancer Discovery
- Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
- (2019) Ana De Jesus-Acosta et al. BRITISH JOURNAL OF CANCER
- Precision medicine for human cancers with Notch signaling dysregulation (Review)
- (2019) Masuko Katoh et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Ferroptosis is a lysosomal cell death process
- (2018) Huan Gao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
- (2018) Natalie Cook et al. BRITISH JOURNAL OF CANCER
- NF-κB in pancreatic cancer: Its key role in chemoresistance
- (2018) Quanxiao Li et al. CANCER LETTERS
- First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
- (2018) C Massard et al. ANNALS OF ONCOLOGY
- Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells
- (2018) Rajpal S. Burmi et al. CANCER BIOLOGY & THERAPY
- KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer
- (2018) Yeo Wool Kang et al. CANCER LETTERS
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
- (2018) Davide Melisi et al. BRITISH JOURNAL OF CANCER
- CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- (2017) Marianne Sinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
- (2017) Seung-Min Shin et al. Nature Communications
- TGF-β in pancreatic cancer initiation and progression: two sides of the same coin
- (2017) Wei Shen et al. Cell and Bioscience
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
- (2017) Diána Brauswetter et al. PLoS One
- GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment
- (2017) Quan Zhou et al. Scientific Reports
- Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer
- (2016) Bo Zhang et al. BIOMATERIALS
- DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer
- (2016) A Drouillard et al. BRITISH JOURNAL OF CANCER
- Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients
- (2016) Motoki Miyazawa et al. INTERNATIONAL JOURNAL OF CANCER
- Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
- (2016) S.-H. Chen et al. Cancer Discovery
- LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
- (2016) Eliza Vakana et al. Oncotarget
- Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma
- (2016) Matthew H. Wong et al. NEOPLASIA
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
- (2015) B. H. O'Neil et al. ANNALS OF ONCOLOGY
- A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†
- (2015) C. S. Fuchs et al. ANNALS OF ONCOLOGY
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
- (2015) A. H. Ko et al. CLINICAL CANCER RESEARCH
- Sonidegib: First Global Approval
- (2015) Celeste B. Burness DRUGS
- Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance
- (2015) C. Duluc et al. EMBO Molecular Medicine
- mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer
- (2015) Feng Wei et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
- (2015) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- Minnelide effectively eliminates CD133+ side population in pancreatic cancer
- (2015) Alice Nomura et al. Molecular Cancer
- Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer
- (2015) S Zhang et al. ONCOGENE
- Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status
- (2015) Florence Huguet et al. Targeted Oncology
- GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells
- (2014) Jian-ying Tang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Mirk/dyrk1B kinase is upregulated following inhibition of mTOR
- (2014) Xiaobing Deng et al. CARCINOGENESIS
- Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K-Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
- (2014) M. H. Wong et al. CLINICAL CANCER RESEARCH
- A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
- (2014) D. C. Smith et al. CLINICAL CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
- (2014) Ana De Jesus-Acosta et al. INVESTIGATIONAL NEW DRUGS
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
- (2014) Melissa Dumble et al. PLoS One
- Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells
- (2013) Ingrid Espinoza et al. CANCER LETTERS
- Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer
- (2013) Shinichi Yabuuchi et al. CANCER LETTERS
- Cyclopamine, a Naturally Occurring Alkaloid, and Its Analogues May Find Wide Applications in Cancer Therapy
- (2013) Haikuo Ma et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Trametinib: First Global Approval
- (2013) Cameron J. M. Wright et al. DRUGS
- A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
- (2013) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Cetuximab: still an option in the treatment of pancreatic cancer?
- (2013) Luca Faloppi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling
- (2013) Elissaveta Petrova et al. Nature Chemical Biology
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disrupting Cytokine Signaling in Pancreatic Cancer
- (2013) Christina Wu et al. PANCREAS
- Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models
- (2013) Hua Zhong et al. PLoS One
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
- (2012) A. Gonçalves et al. ANNALS OF ONCOLOGY
- Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)
- (2012) Volker Heinemann et al. GUT
- The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models
- (2012) M. Mizuma et al. MOLECULAR CANCER THERAPEUTICS
- Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
- (2011) Karl-Hermann Schlingensiepen et al. CANCER SCIENCE
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice
- (2011) Eleni Maniati et al. JOURNAL OF CLINICAL INVESTIGATION
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- (2010) Milind M Javle et al. BMC CANCER
- Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
- (2010) I Garrido-Laguna et al. BRITISH JOURNAL OF CANCER
- Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
- (2010) Dirk Strumberg et al. INVESTIGATIONAL NEW DRUGS
- Gefitinib Inhibits the Proliferation of Pancreatic Cancer Cells via Cell Cycle Arrest
- (2009) Xiaohua Zhou et al. Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology
- Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma
- (2009) Ruben Plentz et al. GASTROENTEROLOGY
- Pancreatic cancer: molecular pathogenesis and new therapeutic targets
- (2009) Han H. Wong et al. Nature Reviews Gastroenterology & Hepatology
- Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer
- (2009) J M Bailey et al. ONCOGENE
- Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
- (2008) C. R. Patra et al. CANCER RESEARCH
- Hedgehog: functions and mechanisms
- (2008) M. Varjosalo et al. GENES & DEVELOPMENT
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started